Quantia

Quick links to important sections

Quantia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quantia

What is Quantia? — Identity and Quick Facts

The drug Quantia is a prescription-only medicine containing the active ingredient Quetiapine, designed to modulate key chemical systems in the brain.

Property Description
Active ingredient Quetiapine (typically as Quetiapine fumarate)
Form Oral tablets (Immediate-Release and Extended-Release)
Pharmacological class Atypical Antipsychotic Agent (Second-Generation)
Common use Modulation of major depressive disorder and symptoms of schizophrenia
Origin Synthetic compound / Dibenzothiazepine derivative

Quetiapine: Defining the Atypical Antipsychotic Agent

The core of Quantia is the active substance Quetiapine, often administered as the salt form, Quetiapine fumarate. This synthetic compound is structurally classified as a dibenzothiazepine derivative. The drug is formally identified as a psycholeptic and belongs to the atypical antipsychotic agent class. As a single-ingredient product, its function is entirely dedicated to regulating activity within the Central Nervous System (CNS). Quetiapine is used in stabilizing complex psychiatric conditions, supporting its established use among adults and adolescents.

How Quantia Works (General Principle and Purpose)

Quantia functions primarily as a serotonin-dopamine antagonist (SDA), meaning its mechanism principle is the selective modulation of key chemical messengers, principally dopamine and serotonin, by blocking their corresponding receptor sites. This targeted action on multiple neurotransmitter systems supports a more normalized pattern of neural communication. Quetiapine is widely used to assist in the management of conditions like schizophrenia and major depressive disorder. The general purpose of the medicine is therefore to help stabilize thought processes, emotional regulation, and overall mental function that may be disrupted by chemical imbalances.

What Form Does Quantia Come In?

Quetiapine is designed for oral administration and is consistently provided as tablets. These pharmaceutical preparations are available in two principal forms: the immediate-release tablet and the extended-release tablet. The immediate-release form allows for rapid absorption of the Quetiapine ingredient, while the extended-release form is formulated to gradually release the active substance over a sustained period, offering flexibility in therapeutic management. This dual availability is a key differentiating factor, enabling practitioners to select the format most suitable for the required dosing schedule.

Regulatory References

  1. MedlinePlus
  2. U.S. National Library of Medicine
  3. NIH

What side effects are possible with Quantia?

Quantia: Possible Side Effects and Safety Information

The safety profile for Quantia (Quetiapine) is officially documented by frequency and System Organ Class (SOC) based on regulatory standards. The most frequently reported adverse reactions typically involve the Central Nervous System and Metabolism.

Classification Examples of Officially Documented Adverse Reactions
Very Common (geq 1/10) Somnolence (drowsiness), dry mouth, dizziness, weight gain, increased appetite, and high blood lipid levels (triglycerides, total cholesterol).
Common (geq 1/100 to < 1/10) Constipation, orthostatic hypotension, tachycardia (fast heart rate), leukopenia, and elevated blood sugar (hyperglycemia).

Serious adverse reactions, though rare, are prominently featured in regulatory labeling. These include the risk of Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (involuntary movements), and severe metabolic changes that may affect blood sugar and lipid levels. The label also contains a Boxed Warning concerning increased mortality when used in elderly patients with dementia-related psychosis, an unapproved use.

Safety statements for specific patient groups note a higher incidence of increased appetite and extrapyramidal symptoms in children and adolescents. Risks such as Orthostatic Hypotension are noted to occur primarily during the initial dose titration period, while long-term use has been associated with cataracts (lens changes). Known hypersensitivity to Quetiapine Fumarate and concurrent use with strong CYP3A4 inhibitors are formal safety restrictions. The overall safety structure highlights the necessity for monitoring metabolic and cardiovascular parameters, as defined by the official labeling.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Quantia (Quetiapine) overdose documents a range of severe clinical manifestations primarily affecting the Central Nervous System (CNS) and Cardiovascular System. Acute overdose exposure can lead to rapid and pronounced CNS depression, which may present as severe somnolence and sedation, potentially progressing to coma. Other documented manifestations include seizures and delirium.

Cardiovascular instability is a major component of the overdose profile, characterized by hypotension (low blood pressure) and sinus tachycardia. Severe or life-threatening outcomes reported in regulatory materials include severe respiratory failure, QT interval prolongation (a serious cardiac rhythm abnormality), and in rare cases, death.

Given the potential for these outcomes, official guidance mandates that individuals seek immediate medical attention for any suspected overdose. Hospitalization or transfer to an Intensive Care Unit (ICU) may be necessary. Management is strictly limited to symptomatic and supportive treatment, as no specific antidote is known. Required supportive steps involve maintaining an open airway and ensuring continuous Cardiac Monitoring (ECG). Overdose symptoms, including coma and hypotension, have been specifically documented in elderly patients.

Therapeutic Uses of Quantia

What Quantia Treats: Main Uses and Benefits

Quantia (Quetiapine) is used across therapeutic domains involving significant symptom expression, generally providing support that may help to ease the overall symptom burden in complex psychiatric conditions. The core therapeutic domains are relevant in clinical settings marked by heightened patient distress, particularly when symptoms create noticeable interference with daily stability.

The medication is commonly used across conditions presenting with acute episodes, including schizophrenia, bipolar disorder (for both manic and depressive episodes), and as adjunctive treatment for Major Depressive Disorder (MDD) when the patient has had an inadequate response to standard therapy.

It is relevant for managing symptom clusters that may become intense or disruptive, such as hallucinations, delusions, severe thought disorder, and the extremes of mood dysregulation.

“The primary goal is to provide supportive relief during difficult episodes, and may provide support that can assist the patient in coping more steadily with symptom fluctuations.”

Quantia is applied during phases where the patient experiences heightened discomfort, and may offer supportive relief when symptoms interfere with routine activities. It can assist with maintaining a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.


Quick Fact: Relief for Psychotic Symptoms and Mood Extremes

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Quantia (Quetiapine Fumarate) — Official Regulatory Information

The eligibility profile for quetiapine is defined by clear contraindications and specific requirements for conditional use as established in governmental regulatory documents (e.g., FDA, EMA).

Mandatory Exclusions (Contraindications)

The medicine must not be used in patients with:

  • A known hypersensitivity or allergy to quetiapine or any of its ingredients.
  • Concomitant administration of potent CYP3A4 inhibitors, such as HIV protease inhibitors (e.g., indinavir), azole-antifungals (e.g., ketoconazole), erythromycin, or nefazodone, due to the risk of significantly increased drug levels.
  • Elderly patients with dementia-related psychosis, as this population has been associated with an increased risk of death when treated with antipsychotic drugs.

Age and Condition Restrictions

Population Group Eligibility Status Regulatory Requirement
Children under 10 Not Approved / Not Recommended Safety and effectiveness have not been established.
Elderly Patients (General Use) Conditional Use A lower starting dose, slower titration, and careful monitoring are required.
Hepatic Impairment Conditional Use Requires a lower starting dose and cautious titration due to liver metabolism.
Pregnancy Conditional Use Use only if the potential benefit justifies the potential risk to the fetus; third-trimester exposure carries risk of neonatal withdrawal symptoms.
Lactation Not Recommended Quetiapine is present in human milk; the official recommendation is to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Quantia Interactions with Other Medicines and Products

Quantia (quetiapine) exhibits a clinically significant interaction profile primarily rooted in its metabolism and pharmacodynamic effects, as documented in regulatory labeling.

Primary Interaction Categories

The most critical interaction involves the Cytochrome P450 3A4 (CYP3A4) enzyme, which is essential for Quantia's breakdown.

Category Regulatory Constraint Examples (Non-Exhaustive List)
CYP3A4 Strong Inhibitors Contraindicated due to significant increase in Quantia exposure. Ketoconazole, HIV-protease inhibitors, Erythromycin.
CYP3A4 Strong Inducers Requires professional management due to substantial decrease in Quantia exposure. Phenytoin, Carbamazepine, Rifampicin.

Pharmacodynamic and Product Interactions

Co-administration with other Central Nervous System (CNS) depressants and alcohol is restricted due to the documented risk of additive depressant effects. Caution is also advised with medicines known to prolong the QT interval due to the potential for additive effects.

Regulatory information notes that food intake affects the systemic exposure of Quantia. Additionally, the herbal product St. John's Wort is classified as an inducer that can lower Quantia levels. Patients with hepatic impairment may require special consideration regarding interaction management.

Mechanism of Action

Quantia functions as a non-competitive allosteric antagonist of the P2Y12 receptor, which is prominently expressed on the surface of circulating platelets. The drug’s binding to a site distinct from the P2Y12 receptor’s endogenous ligand pocket induces a conformational change, thereby preventing the signal transduction mediated by adenosine diphosphate (ADP).

This allosteric modulation inhibits the downstream signaling cascade necessary for platelet activation. Specifically, it blocks the activation of the GPIIb/IIIa complex, a crucial fibrinogen receptor. Suppression of this ADP-dependent pathway fundamentally impedes the physiological processes required for platelet aggregation and the stabilization of thrombus formation within the vasculature, resulting in attenuated platelet-platelet cohesion and reduced thrombus growth.

Dosage and Administration Information

The medicine Quantia (Quetiapine) is approved for oral administration and is available as two primary preparations: the Immediate-Release (IR) tablet and the Extended-Release (ER) tablet. Guidelines for use are structured around the specific properties of these formulations.


Dosing Schedule and Titration

Treatment protocols define an initial titration phase, requiring the starting dose to be low and gradually increased over the first several days until the necessary adult maintenance range is achieved. Maintenance dosages vary by condition but typically fall between 150 mg and 800 mg daily, with a distinct maximum dosage established for each use.

Frequency and Administration Conditions

IR tablets are typically taken in a divided regimen (two or three times daily) and can be administered with or without food. In contrast, ER tablets are prescribed once daily, preferably in the evening, and must be taken either without food or with only a light meal (approximately 300 calories).

Procedural Rules

The extended-release formulation has a strict procedural constraint: the tablet must be swallowed whole and cannot be split, chewed, or crushed, as this action alters the intended slow-release function. For patient populations such as older adults or those with hepatic impairment, the initial starting dose is reduced, and the dose titration must proceed at a slower, more cautious rate. If a dose is missed, guidelines advise against taking a double dose; the patient should take the next dose at the regularly scheduled time.

Recent Clinical Evidence

Research evidence / Overview of Studies for Quantia

This overview summarizes the research that has been conducted on the active ingredient in Quantia, Quetiapine, focusing on the types of studies, what they measured, and what remains uncertain, based only on official regulatory and scientific sources. The findings describe group patterns observed in studies, not personal outcomes or clinical recommendations.


Evidence for Use in Schizophrenia

The research base for this condition primarily involves Randomized Controlled Trials (RCTs). These studies were designed to explore how symptoms change over time for both adults and adolescents who were experiencing acute episodes. Researchers used standardized scales, such as the Brief Psychiatric Rating Scale (BPRS), to monitor measured changes in outcomes related to symptoms. Long-term studies were also conducted to examine the risk of relapse or re-emergence of symptoms, contributing to the evidence base for maintenance settings. Research highlights changes measured during the study period, contributing to the evidence regulators review regarding symptom evolution.

Evidence for Use in Bipolar I and II Disorder

The evidence landscape covers both acute manic episodes and acute depressive episodes, primarily through short-term RCTs. For acute mania, studies explored how symptoms change over time in adults and, in some cases, children and adolescents, using scales like the Young Mania Rating Scale (YMRS). For acute depression, research focused on episodes where symptoms become more noticeable, measuring changes using scales like the Montgomery-Åsberg Depression Rating Scale (MADRS). Findings describe patterns observed in these studies compared to inactive treatment during the typical trial period.

Evidence for Use as Adjunctive Treatment for Major Depressive Disorder (MDD)

Studies explored the use of the medicine as an add-on treatment for a specific patient group: adults who had an inadequate response to an existing antidepressant. These trials monitored short-term changes in depressive symptom severity (MADRS scores) and the frequency of participants meeting criteria for symptom resolution. Results apply only to this highly specific population, and the limited follow-up durations provide limited insight into long-term outcomes for this patient group.

Research Gaps and Areas of Uncertainty

Regulatory and scientific literature frequently highlight evidence gaps. While maintenance studies exist, long-term outcomes are not fully established regarding sustained functional measurements, as follow-up durations were limited in certain study types. Research for younger populations is generally less extensive than for adults. Furthermore, comparative evidence is lacking in some areas, meaning direct head-to-head research against certain other treatments is not always available or consistent. These limitations highlight that research is ongoing and continually contributes to the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Quantia (FAQ)


Q: Why is Quantia a prescription-only medicine?

Quantia is a prescription-only medicine because it belongs to a class of drugs called Atypical Antipsychotics. This class of medication is associated with certain known risks, such as metabolic changes and serious adverse reactions, as described in regulatory documents.

Because of these factors, ongoing professional monitoring and supervision are required for its use, necessitating a prescription.


Q: Does Quantia have a generic version available?

Yes, regulatory bodies have approved generic versions of the drug, which contain the active ingredient Quetiapine fumarate. The official drug approval process requires that these generic versions demonstrate bioequivalence (meaning they work the same way in the body) to the original brand name product.


Q: Can Quantia be used for conditions other than the main approved use?

Official government documents outline the specific conditions for which Quantia has been approved. These approved uses include Schizophrenia, Bipolar Disorder, and use as an add-on treatment for Major Depressive Disorder.

The regulatory information focuses exclusively on these defined indications.


Q: How quickly is Quantia expected to start working?

Official patient information indicates that measuring the full effect of the medicine may take several weeks to two or three months to complete.

While changes related to certain symptoms may be noted sooner, the time required to measure the full effect in clinical studies typically extends to several months.


Q: How long does the effect of one dose of Quantia last?

The duration of the effect is related to the specific tablet formulation. The immediate-release tablet is typically prescribed to be taken in divided doses, one to three times per day.

In contrast, the extended-release tablet is taken once daily and is formulated to release the active substance over a sustained period.


Q: Is a headache a common side effect of Quantia?

Yes, headache is a documented adverse reaction reported in clinical studies of this medication. This information is included in the official safety profile reviewed by regulatory authorities.


Q: Do the side effects of Quantia usually go away over time?

Some side effects, as noted in the official prescribing information, are associated primarily with the start of treatment. For instance, orthostatic hypotension (a drop in blood pressure when standing) is noted to occur mainly during the initial dose titration period.

The product labeling notes that the course of side effects can vary, and the full safety profile is available in the official prescribing information.


Q: Does Quantia cause weight gain or weight loss?

According to official documentation, weight gain is a very common adverse reaction associated with the use of Quetiapine.

This is one of the metabolic changes that requires monitoring during treatment, as described in the official safety guidelines.


Q: Can Quantia affect your sleep schedule?

Drowsiness (somnolence) is a very common side effect of this medicine. Consistent with this known property, the extended-release tablet is generally recommended to be administered once daily in the evening.


Q: Are there any common foods or drinks that interact with Quantia?

Food intake is documented to affect the systemic exposure of the drug in the body. Co-administration with alcohol is restricted due to the potential for additive depressant effects.

Additionally, regulatory information suggests that the consumption of grapefruit and grapefruit juice should be limited due to potential interactions.


Q: Does Quantia interact with common pain relievers like ibuprofen?

Official product information notes that certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs) carry a general risk of gastrointestinal side effects.

Official information emphasizes that the prescribing doctor should be informed of all concomitant medications, including pain relievers, to review potential risks.


Q: Can you take Quantia with multivitamins or supplements?

The herbal product St. John's Wort is documented in official labeling as a substance that can interact and lower drug levels.

The professional prescribing information states that prescribers should be made aware of all supplements and vitamins being taken, as concurrent use may require management.


Q: Is Quantia considered a controlled substance?

No, Quetiapine is not classified as a controlled substance under the U.S. Controlled Substances Act.

It is available as a prescription-only medicine due to the risks associated with its pharmacological class.


Q: What is the long-term safety profile of Quantia?

Official regulatory information notes that long-term use has been associated with cataracts (lens changes).

Furthermore, scientific reviews highlight that long-term functional outcomes regarding sustained wellness have not been fully established in all patient populations studied.


Q: Is Quantia safe for use during pregnancy?

Official documentation describes that use during pregnancy requires a weighing of potential benefit against potential risk to the fetus.

Exposure during the third trimester is documented to carry a risk of neonatal withdrawal symptoms after birth.


Q: Is Quantia safe for people with kidney problems?

According to the official product information, dosage adjustment is typically not needed for patients with mild to severe renal (kidney) impairment.

The official documents note that professional assessment is necessary before use in all special patient groups, including those with kidney issues.


Q: Are there ongoing clinical trials for new uses of Quantia?

Clinical research into the drug's active ingredient is continuous. Governmental resources, such as ClinicalTrials.gov, list studies that have been completed and may currently be active for various uses and patient groups.

This information contributes to the broader regulatory evidence base.


Q: Where can I find the official prescribing information for Quantia?

Official documents, such as the Medication Guide and the full Prescribing Information, can typically be obtained from the prescribing doctor or pharmacist. These documents are also available on government regulatory websites like the FDA.


Q: Is it possible to develop a tolerance to Quantia?

Tolerance (where the body needs more of the drug for the same effect) and sensitization (where the body becomes more responsive) are recognized concepts in the context of chronic antipsychotic treatment.

These effects reflect the brain's adaptive response to the consistent presence of the drug.


Q: Can Quantia be crushed or split?

The extended-release tablet has a strict procedural constraint in its official instructions: it must be swallowed whole.

Regulatory information states that crushing or splitting this tablet is not permitted because it alters the intended slow-release function of the drug.


Q: Does taking Quantia require regular blood tests or monitoring?

Yes, official safety structure highlights the necessity for monitoring. Regular checks of metabolic parameters, such as blood sugar and lipid levels, and cardiovascular status are required.

Routine monitoring of body weight is also necessary during treatment.


Q: What happens when you stop taking Quantia?

Abruptly stopping the drug may cause acute withdrawal symptoms, which could include nausea, vomiting, or insomnia.

The product information states that gradual dose reduction under the supervision of a healthcare professional is necessary.


Q: Is Quantia a drug that is taken short-term or long-term?

The required duration of use is dependent on the specific approved condition being addressed. The drug is approved for the acute (short-term) treatment of certain conditions and for the long-term maintenance of other conditions.


Q: Is Quantia safe to take with blood pressure medications?

Quantia may cause a reduction in blood pressure, noted as a common side effect (orthostatic hypotension).

Caution is advised when co-administering the drug with other medications that are known to also affect or lower blood pressure.


Q: What is the shelf life of Quantia tablets?

The approved shelf life for the tablets, when stored according to official instructions at controlled room temperature (20 C to 25 C), is typically 36 months from the date of manufacture.

This duration is based on stability data reviewed by regulatory authorities.


Q: Can Quantia affect my ability to drive or operate machinery?

Because the drug may cause dizziness, drowsiness, and impaired judgment, the official warnings advise caution.

The official warning states that driving or operating hazardous machinery is not recommended until the individual is aware of how the medicine affects their ability.


Q: What is the difference between the brand name and generic versions of Quantia?

The active ingredient in both the brand name and the generic version is the same: Quetiapine fumarate.

Regulatory bodies require that all approved generic versions demonstrate bioequivalence, meaning they must work the same way in the body as the brand name product.


Q: Are allergic reactions to Quantia common?

A known hypersensitivity (allergic reaction) to Quetiapine Fumarate is a mandatory exclusion, or contraindication, for its use.

While this is a serious risk, the frequency of allergic reactions to the medicine is generally low as documented in the official safety profile.


Q: Is Quantia the same as [Name of a similar-sounding drug]?

Regulatory agencies have historically issued warnings regarding the potential for confusion between Quetiapine and other similar-sounding drug names.

Official information highlights the importance of verifying the drug name and spelling on the prescription or label with a healthcare professional.

How should Quantia be stored and disposed of?

How to Store and Dispose of Quantia?

Quantia (Quetiapine) must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Official Storage Conditions

Requirement Specific Rule
Temperature Store at controlled room temperature, typically 20 C to 25 C (68°F to 77°F).
Protection Keep away from excess heat and moisture; do not store in the bathroom or freeze.
Packaging Keep the medication in the original container and ensure the container is tightly closed.

Handling and Disposal Rules

The medicine must be stored out of the sight and reach of children, with safety caps locked. For disposal, unused or expired tablets should not be flushed down the toilet or sink. The preferred method is using a drug take-back program. If this is unavailable, the regulatory instruction is to mix the tablets with an undesirable substance (like dirt) in a sealed bag before throwing them into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quantia found in:

A-Z Index: